Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus bevacizumab with or without external radiation therapy for hepatocellular carcinoma with macrovascular invasion
KCT0007365Phase 2Active, not recruiting
- Sponsor
- Asan Medical Center
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Asan Medical Center. Started Oct 2022; status: active, not recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0007365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007365.